BOUCHERVILLE, QUÉBEC, October 24, 2024 - LSL PHARMA GROUP INC. (TSXV: LSL) ("LSL Pharma” or the "Corporation"), an integrated Canadian-based pharmaceutical company, reports that it will make on October 31, 2024, the first interest payment (the “Interest Payment”) on its outstanding Unsecured Redeemable Debentures (the “Debentures”) listed on the TSXV under symbol “LSL.DB”. The Corporation will pay to each Debenture holder an amount of $113.025 per $1,000 principal amount of Debentures which represents accrued interest payable from November 1, 2023, to October 31, 2024.

The Debentures which may be redeemed by the Corporation, have a maturity date of October 31, 2028 (the “Maturity Date “), and accrue interest at the rate of 11% per annum (from October 31, 2024 to but excluding April 30, 2025, subject to adjustments thereafter) payable semi-annually on the last day of April and October of each year with the next interest payment to take place on April 30, 2025. At the holders' option, the Debentures may be converted into Class A shares of the Corporation at any time and from time to time, up to the Maturity Date, at a conversion price of $0.70 per Class A share.

For additional details regarding the Debentures, please refer to the Debenture Indenture dated November 1, 2023, which is available under LSL Pharma’s issuer profile on www.sedarplus.ca.

About LSL Pharma Group Inc.

LSL Pharma Group Inc. is an integrated Canadian-based pharmaceutical company specializing in the development, manufacturing, and commercialization of high-quality sterile ophthalmic pharmaceuticals, as well as natural health products in solid and liquid dosage forms. For further information, please visit our website at www.groupelslpharma.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact

François Roberge

President and Chief Executive Officer

(514) 664-7700

E-mail: froberge@groupelslpharma.com 

Or

Luc Mainville

Executive Vice-President and Chief Financial Officer

(514) 664-7700 Ext: 301

E-mail : lmainville@groupelslpharma.com